Business
First European Site Opens - Patient Recruitment
First European Site Opens - Patient Recruitment.
About this update from Immupharma Plc
[{"type":"text","content":"\n \nRNS Number : 4663R Immupharma PLC 09 March 2016 \n\n\n\n\n\nRNS : FOR IMMEDIATE RELEASE\n\n\n9 MARCH 2016\n\n\n\n\n \n \nFIRST EUROPEAN SITE OPENED IN FRANCE AND PATIENT RECRUITMENT COMMENCES \nIN LUPUZOR'S PIVOTAL PHASE III STUDY\n \n \nImmuPharma PLC (LSE:IMM), (\"ImmuPharma\" or the \"Company\"), the specialist drug discovery and development company, is pleased to provide a further update on the progress of its pivotal Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto immune disease.\n \nImmuPharma is pleased to confirm that the first European site in Bordeaux, France is open and the patient recruitment process in Europe has now commenced. This follows on from the Company's recent announcement in February that the first US Lupus patients had commenced dosing. \n \nRecruitment in this pivotal Phase III study for Lupuzor™ will occur in up to 45 investigator sites. 10 sites in United States and 35 sites in Europe to include France, Hungary, Poland, Germany, Czech Republic, Italy and the UK.\n \nFurther updates on the progression of the Lupuzor™ Phase III trial will be announced, as appropriate, as the trial progresses. Progress on the trial can also be seen at: www.ClincialTrials.gov/lupuzor.\n \nCommenting on this event, Tim McCarthy, Chairman, said: \"Following the initial US sites being opened and the first Lupus patients having commenced dosing we are delighted that we have hit another key milestone with patient recruitment started in our first European site in France. We look forward to providing further positive updates on this Lupuzor™ Phase III study as it progresses throughout this year and 2017.\" \n \n-Ends-\n\n\n\n\nFor further information please contact:\n \n\n\n\n\nImmuPharma plc (www.immupharma.org)\n\n\n+ 44 (0) 20 7152 4080\n\n\n\n\nTim McCarthy, Chairman\n\n\n\n\n\n\n\nLisa Baderoon, Head of Investor Relations\nTwitter: @immupharma\n \n\n\n + 44 (0) 7721 413496\n \n \n\n\n\n\n \nPanmure, Gordon & Co., NOMAD & Broker\n\n\n \n+44 (0) 20 7886 2500\n\n\n\n\nFred Walsh, Duncan Monteith, Corporate Finance\nCharles Leigh-Pemberton, Corporate Broking\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nNotes to E...